1026876-50-5

Basic information

• Product Name: 5-bromo-4-fluoro-2-hydroxybenzamide
• Synonyms: 5-bromo-4-fluoro-2-hydroxybenzamide
• CAS NO: 1026876-50-5
• Molecular Weight: 234.025
• Mol File: 1026876-50-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-bromo-4-fluoro-2-hydroxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-4-fluoro-2-hydroxybenzamide(1026876-50-5)
• EPA Substance Registry System: 5-bromo-4-fluoro-2-hydroxybenzamide(1026876-50-5)

Safety Data

• Hazardous Substances Data: 1026876-50-5(Hazardous Substances Data)

Upstream product

• 1644-71-9 5-bromo-4-fluoro-2-hydroxy-benzoic acid 
• 4133-72-6 methyl 5-bromo-4-fluoro-2-hydroxybenzoate 
• 345-29-9 4-fluorosalicylic acid 

Relevant articles and documents

Benzo[1, 3]oxazin-oxazolidinone compounds, and preparation method and application thereof

The invention discloses benzo[1, 3]oxazin-oxazolidinone compounds, and a preparation method and application thereof, and belongs to the technical field of medicines. The invention specifically relates to application in preparation of drugs for treating an

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).